SARAFEM
FLUOXETINE HYDROCHLORIDE
Approval overview SARAFEM is listed in Drugs@FDA under application 021860 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient FLUOXETINE HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor APIL Submission history Latest submission status date: 2021-09-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview SARAFEM is listed in Drugs@FDA under application 021860 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FLUOXETINE HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor APIL Submission history Latest submission status date: 2021-09-20 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.